ILOSONE
LOE ApproachingNDAORALSUSPENSION
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILOSONE is an oral suspension small-molecule antibiotic approved in 1967 by Eli Lilly and Company. The exact mechanism of action and indications are not specified in available data, but the product represents a legacy oral antibiotic formulation. This drug is a mature, established therapy with limited clinical development activity.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting a small, specialized team focused on maintenance and operational efficiency rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ILOSONE currently shows zero linked job openings, reflecting its mature, low-growth status. Career growth on this product is limited; roles focus on maintenance, cost optimization, and supply continuity rather than innovation or market expansion.
Product ManagerBrand Manager
Worked on ILOSONE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.